Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6880604 | 0.83 | CES1 (0.71) | CES1KMT2AKCNN4ALDH1A1NPC1 | |
| SCHEMBL1454439 | 0.83 | CES1 (0.63) | CES1KMT2AMAPTKCNN4ALDH1A1 | |
| SCHEMBL10591841 | 0.80 | ALDH1A1 (0.50) | CES1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL28836942 | 0.79 | KMT2A (0.43) | KMT2AMAPTKCNN4ALDH1A1PARP10 | |
| SCHEMBL4234189 | 0.78 | ALDH1A1 (0.44) | KMT2AMAPTALDH1A1PARP10NPC1 | |
| SCHEMBL8717382 | 0.77 | KMT2A (0.44) | KMT2AMAPTKCNN4ALDH1A1PARP10 | |
| SCHEMBL10583986 | 0.77 | ALDH1A1 (0.52) | CES1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL9277098 | 0.77 | CES1 (0.45) | CES1KMT2AKCNN4ALDH1A1NPC1 | |
| SCHEMBL27540267 | 0.75 | ALDH1A1 (0.42) | KMT2AMAPTALDH1A1PARP10NPC1 | |
| SCHEMBL14101171 | 0.72 | PTPN1 (0.43) | CES1KMT2AMAPTKCNN4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248887-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE, LLC | 2019-08-15 | — | — | US | disclosed |
| US-20160279248-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE, LLC | 2016-09-29 | — | — | US | disclosed |
| US-9364554-B2 | Extracellular targeted drug conjugates | CENTROSE LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-20130336994-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE, LLC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8470980-B2 | Extracellular targeted drug conjugates | CENTROSE, LLC (US) | 2013-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248887-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | FCGR2A, ENGASE, FCER2 | CES1 398/4885KMT2A 2710/4885MAPT 1818/4885 |
| US-20130336994-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | FCGR2A, ENGASE, FCER2 | CES1 398/4885KMT2A 2710/4885MAPT 1818/4885 |
| US-20160279248-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | FCGR2A, ENGASE, FCER2 | CES1 398/4885KMT2A 2710/4885MAPT 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.